Original Review
Buprenorphine for the Treatment of Perinatal Opioid Dependence: Pharmacology and Implications for Antepartum, Intrapartum, and Postpartum Care
Article first published online: 28 APR 2011
DOI: 10.1111/j.1542-2011.2011.00049.x
© 2011 by the American College of Nurse-Midwives
Additional Information
How to Cite
Goodman, D. (2011), Buprenorphine for the Treatment of Perinatal Opioid Dependence: Pharmacology and Implications for Antepartum, Intrapartum, and Postpartum Care. Journal of Midwifery & Womens Health, 56: 240–247. doi: 10.1111/j.1542-2011.2011.00049.x
Publication History
- Issue published online: 28 APR 2011
- Article first published online: 28 APR 2011
- Abstract
- Article
- References
- Cited By
Keywords:
- buprenorphine;
- neonatal abstinence;
- perinatal opioid dependence;
- pregnancy
Opioid dependence during pregnancy is associated with significant health risks for both the mother and her fetus. Opioid maintenance therapy with methadone (Dolophine) is the current standard of care, reduces medical and social risks associated with illicit drug use, and decreases rates of prematurity and low birth weight. However, treatment with methadone is frequently associated with neonatal abstinence syndrome. Buprenorphine is an alternative to methadone that preliminary data indicates is equivalent in safety and efficacy to methadone and significantly increases access to treatment. The pharmacology of buprenorphine and its implications for the care of pregnant women with opioid dependence are described.

1542-2011/asset/olbannerleft.jpg?v=1&s=03aeb3354884183388e0706f0541db283703e09f)
1542-2011/asset/olbannerright.jpg?v=1&s=799c7b68ebfed1f051f2fdc92453e2693b34c2e0)
